The recent identification of DNMT3A mutations in de novo acute myeloid leukemia prompted us to determine their frequency, patterns and clinical impact in a cohort of 98 patients with either therapy-related or secondary acute myeloid leukemia developing from an antecedent hematologic disorder. We identified 24 somatic mutations in 23 patients with a significantly higher frequency in secondary ac...

This summary is intended to update the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) 2020/1 consensus on HSCT for Acute Myeloid leukemia (AML).

We investigated the NPM1 mutation status or subcellular expression of NPM protein (nuclear vs. aberrant cytoplasmic) at diagnosis and relapse in 125 patients with acute myeloid leukemia from Italy and Germany. All 52 patients with acute myeloidleukemia carrying at diagnosis mutated or cytoplasmic NPM (NPMc(+) acute myeloid leukemia) retained this feature at relapse. Notably, cytoplasmic mutated...

some of the genotypes of cytokines are associated with acute graft versus host disease after bone marrow transplantation. the purpose of the present investigation was to find out the possible association between transforming growth factor beta-1 (tgf-β1) codon 25 polymorphism (rs:1800471) and acute graft versus host disease (agvhd) after bone marrow transplantation from the sibling with the sim...

myeloid sarcoma of female breast is a rare presentation of acute myeloid leukemia (aml). the tumor mass may precede or occur concurrently with aml, cml, myeloproliferative disorders, and/or myelodysplastic syndromes. histologically, it looks like a large cell lymphoma and can be misdiagnosed. a case referred as a suspected case of large cell lymphoma. initial morphological study with convention...

BACKGROUND Differences in the clinical course of secondary acute myeloid leukemia according to the type of the preceding disorders are not defined. We compared the outcomes of therapy-related acute myeloid leukemia, acute myeloid leukemia following myelodysplastic syndrome and acute myeloiod leukemia following myeloproliferative neoplasm. We also intended to find prognostic factors in secondary...

The ex vivo sensitivity of pediatric leukemia cells to the proteasome inhibitor bortezomib was compared to 3 next generation proteasome inhibitors: the epoxyketone-based irreversible proteasome inhibitors carfilzomib, its orally bio-available analog ONX 0912, and the immunoproteasome inhibitor ONX 0914. LC50 values were determined by MTT cytotoxicity assays for 29 childhood acute lymphoblastic ...

introduction: about half of acute myeloid leukemia (aml) adult patients have no cytogenetic abnormalities as a main determinant of complete remission after treatment, so other markers are needed such as flt3-itd (fms-like tyrosine kinase3-internal tandem duplication) mutations in patients with normal karyotype. the objective of this study was assessing the frequency of flt3-itd mutations and it...

BACKGROUND Acute myeloid leukemia is typically a disease of the older population and presents mostly in the fifth decade of life. Myeloid sarcoma is a rare initial presentation of acute myeloid leukemia. Previously it has only been documented in children and younger patients. CASE PRESENTATION We present an unusual case of retro-orbital myeloid sarcoma as an initial presentation of acute myel...

post-remission treatment in patients with acute myeloid leukemia is still controversial. one potent choice for patients with no donor available is autologous stem cell transplantation. the median follow-up period was 18 months and the median age was 26 years old. in the review of 116 recently diagnosed aml patients (except aml- m3) who underwent autologous stem cell transplantation, 72.4% of pa...